RxDoctor Payments Data

Jerry McLain, MD

Family Medicine · Chadron, NENPI 1912980327

Payments from drug & device makers

$797in general payments, 2019–2025

Across 45 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$172
  • Novartis$106
  • Xeris Pharmaceuticals, Inc.$88
  • Verona Pharma, Inc.$57
  • Sanofi-aventis U.S. LLC$47
  • Lilly USA, LLC$43
  • plus $284 from 11 others

What the payments were for

  • Food & beverage$797100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$797 in reported general payments places this provider in the 55th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$168,475
Medicare patients
493
Services billed
2,450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban206$139,531
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog56$30,743
JanuviaSitagliptin Phosphate30$28,830
JardianceEmpagliflozin20$28,794
XareltoRivaroxaban26$28,666
XifaxanRifaximin12$14,962
OzempicSemaglutide16$13,810
FarxigaDapagliflozin Propanediol16$12,962
MyrbetriqMirabegron24$12,452
Spiriva HandihalerTiotropium Bromide16$11,821
Breo ElliptaFluticasone/Vilanterol29$11,195
Spiriva RespimatTiotropium Bromide13$9,898
InvokanaCanagliflozin12$8,051
SymbicortBudesonide/Formoterol Fumarate31$7,243
Combivent RespimatIpratropium/Albuterol Sulfate14$6,702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto, Invokana$41$36,71638 claims
MerckJanuvia, Dulera$17$33,28444 claims
AstraZenecaFarxiga, Symbicort$37$20,20547 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Chadron

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →